[1]王华 陈科宇 秦永文 白元.新型卵圆孔未闭封堵器的研制及临床应用进展[J].心血管病学进展,2023,(9):781.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.004]
　WANG Hua,CHEN Keyu,QIN Yongwen,et al.Design and Clinical Practice of Novel Patent Foramen Ovale Occluders[J].Advances in Cardiovascular Diseases,2023,(9):781.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.004]
点击复制

新型卵圆孔未闭封堵器的研制及临床应用进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年9期
页码:
781
栏目:
综述
出版日期:
2023-09-25

文章信息/Info

Title:
Design and Clinical Practice of Novel Patent Foramen Ovale Occluders
作者:
王华 陈科宇 秦永文 白元
(海军军医大学第一附属医院心血管内科,上海 200433)
Author(s):
WANG Hua; CHEN Keyu; QIN Yongwen; BAI Yuan
(Department of Cardiology,The First Affiliated Hospital of Naval Medical University,Shanghai 200433,China)
关键词:
卵圆孔未闭; 器械; 卒中; 偏头痛
Keywords:
Patent foramen ovale; Device; Stroke; Migraine
DOI:
10.16806/j.cnki.issn.1004-3934.2023.09.004
摘要:
卵圆孔是房间隔上一个先天性的薄弱区域，约75%的人群在婴幼儿期均会自行关闭，少数人成年后仍未能自行关闭称之为卵圆孔未闭（PFO）。近几年，经导管PFO封堵术在PFO相关卒中或偏头痛的循证证据逐年增加。目前 美国食品和药物管理局批准应用于临床的PFO封堵器械有Amplatzer PFO封堵器和Gore Cardioform PFO封堵器，其他封堵器也在临床上广泛应用。但现有器械仍存在术后新发心房颤动、封堵器相关血栓、房间隔周围组织磨蚀等封堵器相关并发症，新型PFO封堵器械的研发一直是行业热点，现对这一领域的研究进展做一综述。
Abstract:
?oramen ovale is an embryonic defect in the interatrial septum. About 75% of the population will self close during infancy,and a few people may still fail to self close after adulthood,which is called patent foramen ovale(PFO). In recent years,the evidence-based data on transcatheter PFO occlusion for the treatment of PFO-related stroke or migraine is increasing year by year. Currently,the PFO occluder devices approved by the US Food and Drug Administration for clinical use include Amplatzer PFO occluder and Gore Cardioform PFO occluder. Other occluder devices are also widely used in clinical practice. However,the existing devices still have occluder-related complications such as new-onset atrial fibrillation after surgery,occluder-related thrombus,and tissue abrasion around the atrial septum. The research and development of novel PFO occluder devices has always been a hot spot in the industry. Now,this paper reviews the research progress in this field

参考文献/References:

[1] Teshome MK,Najib K,Nwagbara CC,et al. Patent foramen ovale:a comprehensive review[J]. Curr Probl Cardiol,2020,45(2):100392.

[2] Mojadidi MK,Zaman MO,Elgendy IY,et al. Cryptogenic stroke and patent foramen ovale[J]. J Am Coll Cardiol,2018,71(9):1035-1043.

[3] Man H,Xu Y,Zhao Z,et al. The coexistence of a patent foramen ovale and obstructive sleep apnea may increase the risk of wake-up stroke in young adults[J]. Technol Health Care,2019,27(S1):23-30.

[4] Giblett JP,Williams LK,Kyranis S,et al. Patent foramen ovale closure:state of the art[J]. Interv Cardiol,2020,15:e15.

[5] Mas JL,Derumeaux G,Guillon B,et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke[J]. N Engl J Med,2017,377(11):1011-1021.

[6] Alkhouli M,Sievert H,Holmes DR.. Patent foramen ovale closure for secondary stroke prevention[J]. Eur Heart J,2019,40(28):2339-2350.

[7] Saver JL,Carroll JD,Thaler DE,et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke[J]. N Engl J Med,2017,377(11):1022-1032.

[8] Iskander B,Anwer F,Oliveri F,et al. Amplatzer patent foramen ovale occluder device-related complications[J]. Cureus,2022,14(4):e23756.

[9] Madhkour R,Wahl A,Praz F,et al. Amplatzer patent foramen ovale occluder:safety and efficacy[J]. Expert Rev Med Devices,2019,16(3):173-182.

[10] Santoro G,Castaldi B,Cuman M,et al. Trans-catheter atrial septal defect closure with the new GORE? Cardioform ASD occluder: first European experience[J]. Int J Cardiol,2021,327:68-73.

[11] Carroll JD,Saver JL,Thaler DE,et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke[J]. N Engl J Med,2013,368(12):1092-1100.

[12] S?ndergaard L,Kasner SE,Rhodes JF,et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[J]. N Engl J Med,2017,377(11):1033-1042.

[13] No authors listed. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[J]. N Engl J Med,2020,382(10):978.

[14] Neuser J,Akin M,Bavendiek U,et al. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla? Flex Ⅱ Occluder[J]. BMC Cardiovasc Disord,2016,16(1):217.

[15] Snijder RJR,Renes LE,Suttorp MJ,et al. Percutaneous patent foramen ovale closure using the Occlutech Figulla device:more than 1,300 patient-years of follow up[J]. Catheter Cardiovasc Interv,2019,93(6):1080-1084.

[16] Hildick-Smith D,Williams T,MacCarthy P,et al. Occlutech percutaneous patent foramen ovale closure:safety and efficacy registry(OPPOSE)[J]. Int J Cardiol,2017,245:99-104.

[17] Apostolopoulou SC,Tsoutsinos A,Laskari C,et al. Large single centre experience with the Cera? and CeraFlex? oc cluders for closure of interatrial communications:usefulness of the flexible rotation feature[J]. Cardiovasc Interv Ther,2018,33(1):70-76.

[18] Fritz C,Engelhardt A,Grohmann J,et al. A multi-center trial on efficacy and safety of the LifeTech CeraFlexTM ASD occluder for transcatheter closure in patients with secundum atrial septal defects[J]. Cardiovasc Diagn Ther,2022,12(4):475- 484.

[19] Kenny D,Morgan GJ,Bentham JR,et al. Early clinical experience with a modified Amplatzer ductal occluder for transcatheter arterial duct occlusion in infants and small children[J]. Catheter Cardiovasc Interv,2013,82(4):534-540.

[20] Labombarda F,Roule V,Beygui F. Delayed spontaneous perforation of polyvinyl alcohol membrane- covered atrial septal defect closure devices[J]. Catheter Cardiovasc Interv,2017,89(4):E141-E144.

[21] Araszkiewicz A,S?awek S,Trojnarska O,et al. Interventional closure of patent foramen ovale with Nit-occlud? device in prevention of recurrent neurologic events-Long-term results[J]. Catheter Cardiovasc Interv,2018,92(1):159- 164.

[22] Levy Y,Jalal Z,Aussel A,et al. In vitro comparison of three percutaneous atrial septal defect closure devices for endothelialisation and haemocompatibility[J]. Arch Cardiovasc Dis,2020,113(8-9):503-512.

[23] Jalal Z,Boudjemline Y,Iriart X,et al. Comparison of two percutaneous atrial septal defect occluders for device healing and nickel release in a chronic porcine model[J]. J Interv Cardiol,2020,2020:8413831.

[24] Li BN,Xie YM,Xie ZF,et al. Study of biodegradable occluder of atrial septal defect in a porcine model[J]. Catheter Cardiovasc Interv,2019,93(1):E38-E45.

[25] Li YF,Xie YM,Chen J,et al. Initial experiences with a novel biodegradable device for percutaneous closure of atrial septal defects:from preclinical study to first-in-human experience[J]. Catheter Cardiovasc Interv,2020,95(2):282-293.

[26] Li Y,Xie Y,Li B,et al. Initial clinical experience with the biodegradable AbsnowTM device for percutaneous closure of atrial septal defect:a 3- year follow-up[J]. J Interv Cardiol,2021,2021:6369493.

[27] Song L,Shi P,Zheng X,et al. Echocardiographic characteristics of transcatheter closure of patent foramen ovale with mallow biodegradable occluder:a single-center,phase Ⅲ clinical study[J]. Front Cardiovasc Med,2022,9:945275.

[28] Du Y,Xie H,Shao H,et al. A Prospective,single-center,phaseⅠclinical trial to evaluate the value of transesophageal echocardiography in the closure of patent foramen ovale with a novel biodegradable occluder[J]. Front Cardiovasc Med,2022,9:849459.

[29] Sigler M,S?derberg B,Schmitt B,et al. Carag bioresorbable septal occluder(CBSO):histopathology of experimental implants[J]. EuroIntervention,2018,13(14):1655-1661.

[30] Sievert K,Bertog S,S?derberg B,et al. Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable septal occluder:first-in-man experience with 24-month follow-up[J]. EuroIntervention,2022,17(18):1536-1537.

[31] Mullen MJ,Hildick-Smith D,de Giovanni JV,et al. BioSTAR Evaluation STudy(BEST):a prospective,multicenter,phaseⅠclinical trial to evaluate the feasibility,efficacy,and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts[J]. Circulation,2006,114(18):1962-1967.

[32] van den Branden BJ,Post MC,Plokker HW,et al. Patent foramen ovale closure using a bioabsorbable closure device safety and efficacy at 6-month follow-up[J]. JACC Cardiovasc Interv,2010,3(9):968-973.

[33] Suligoj NC,Rojko M,Suligoj B,et al. Long-term transesophageal echocardiography after patent foramen ovale closure by BioSTAR and Amplatzer patent foramen ovale occluders[J]. Catheter Cardiovasc Interv,2020,95(3):349-354.

[34] 潘湘斌. 中国原创心血管器械研发的新领域——室间隔缺损可降解封堵器获批上市的启示[J]. 中国循环杂志,2022,37(8):766-768.

[35] Gaspardone A,de Marco F,Sgueglia GA,et al. Novel percutaneous suture-mediated patent foramen ovale closure technique:early results of the NobleStitch EL Italian Registry[J]. EuroIntervention,2018,14(3):e272-e279.

[36] Chaudhry-Waterman N, Shapiro S, Thompson J. Use of the NobleStitch ? EL for the treatment of patients with residual right-to-left shunt following device closure of PFO[J]. Clin Case Rep,2021,9(4):1929- 1932.

[37] Aral M,Mullen M. The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale[J]. Catheter Cardiovasc Interv,2015,85(6):1058- 1065.

[38] Onorato EM,Ambrosini V,Casilli F,et al. Very long-term follow-up after in-tunnel patent foramen ovale closure with FlatStent EF:still an attractive option?[J]. Postepy Kardiol Interwencyjnej,2021,17(3):319-321.

[39] Sievert H,Wunderlich N,Reiffenstein I,et al. Initial clinical experience with the Coherex FlatStent? and FlatStent? EF PFO closure system for in-tunnel PFO closure:results of the Coherex-EU study[J]. Catheter Cardiovasc Interv,2014,83(7):1135-1143.

[40] Lang N,Pereira MJ,Lee Y,et al. A blood-resistant surgical glue for minimally invasive repair of vessels and heart defects[J]. Sci Transl Med,2014,6(218):218ra6.

相似文献/References:

[1]田晓光 陈武 徐琨 刘晓芳.经胸超声心动图声学造影与对比增强经颅多普勒对卵圆孔未闭右向左分流的筛查价值[J].心血管病学进展,2022,(4):371.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.020]
　TIAN Xiaoguang,CHEN WuXU Kun,LIU Xiaofang.The Screening Value of Contrast Transthoracic Echocardiography and Contrast-Enhanced Transcranial Doppler in the Right to Left Shunt of Patent Foramen Ovale[J].Advances in Cardiovascular Diseases,2022,(9):371.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.020]
[2]刘瑶 张丽娟 雍永宏 孙海建.斜卧呼吸-直立性低氧血症综合征机制与诊疗研究进展[J].心血管病学进展,2023,(8):752.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.018]
　LIU Yao,ZHANG Lijuan,YONG Yonghong,et al.Progress on the Mechanism,Diagnosis and Treatment of Platypnea-Orthodeoxia Syndrome[J].Advances in Cardiovascular Diseases,2023,(9):752.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.018]

更新日期/Last Update: 2023-10-17